Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study)

被引：0
|
作者：
Chen, Jinzhang
Zang, Mengya
Pang, Huajin
Li, Chuanjiang
Zhao, Jianbo
Guo, Yabing
Hou, Jinlin
机构：
[1] Southern Med Univ, Hepatol Unit, Nanfang Hosp, Guangzhou, Peoples R China
[2] Southern Med Univ, Dept Infect Dis, Nanfang Hosp, Guangzhou, Peoples R China
[3] Southern Med Univ, Nanfang Hosp, Guangzhou, Peoples R China
[4] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, State Key Lab Organ Failure Res,Guangdong Prov Ke, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
中国国家自然科学基金;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16128
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy of Shipixiaoji Granules, Lenvatinib, and Tislelizumab in Patients with Unresectable Hepatocellular Carcinoma: Protocol for a Prospective, Single-Arm, Phase II Trial
    Zhang, Zhen
    Liang, Zicheng
    Tan, Xiaoning
    Jian, Huiying
    Gao, Wenhui
    Zeng, Puhua
    NATURAL PRODUCT COMMUNICATIONS, 2024, 19 (12)
  • [22] Donafenib combined with camrelizumab and transarterial chemoembolization (TACE) as conversion therapy for unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm, phase II study.
    Cao, Yajuan
    Zhang, Xuebin
    Yue, Yang
    Peng, Jin
    Li, Binghua
    Shi, Jiong
    Tang, Min
    Chen, Chaobo
    Su, Ke
    Zhang, Laizhu
    Cheng, Chunxiao
    Yu, Decai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Neoadjuvant tislelizumab combined with lenvatinib plus transcatheter arterial chemoembolization in resectable hepatocellular carcinoma with high-risk of recurrence: A prospective, single-arm, phase II trial
    Chen, Zhiyu
    Zhang, Leida
    Zhang, Hui
    Gong, Yi
    Feng, Kai
    Ma, Kuansheng
    Bi, Huaqiang
    Xia, Feng
    Dai, Haisu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Camrelizumab in combination with TACE for the treatment of unresectable hepatocellular carcinoma (HCC): A multicenter, single-arm, prospective real-world study.
    You, Ran
    Yin, Guowen
    Xu, Hao
    Zhu, Xiaoli
    Zhang, Qingqiao
    Wang, Qi
    Cao, Chi
    Lu, You
    Jiang, Hao
    Liu, Jun
    Yu, Hui
    Xu, Qingyu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC).
    Vogel, Arndt
    Siegler, Gabriele Margareta
    Siebler, Jurgen
    Lindig, Udo
    Schultheiss, Michael
    Mueller, Tobias
    Simon, Henry
    Joeckel, Christiane
    Mueller, Daniel Wilhelm
    Al-Batran, Salah-Eddin
    Saborowski, Anna
    De Toni, Enrico N.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study.
    Xu, Yongkang
    Fu, Shumin
    Mao, Ye
    Yi, Fengming
    Jiang, Weiming
    Feng, Long
    Wu, Jianbing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 500 - 500
  • [27] Hepatic arterial infusion chemotherapy (HAIC) combined with tislelizumab and lenvatinib for advanced hepatocellular carcinoma (aHCC) with Vp3-4 portal vein tumor thrombosis (PVTT): A single-arm, phase II study
    Xu, Yongkang
    Fu, Shumin
    Mao, Ye
    Huang, Shenglan
    Li, Dan
    Wu, Jianbing
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Adjuvant camrelizumab combined with apatinib treatment after resection of hepatocellular carcinoma in CNLC II and III stage: A single-center prospective phase II trial
    Yang, X.
    Sun, H.
    Hu, B.
    Wu, S-Y.
    Shi, Y-H.
    Wang, X-Y.
    Gao, Q.
    Huang, C.
    Wang, Z.
    Shi, G-M.
    He, Y-F.
    Ding, Z-B.
    Peng, Y-F.
    Sun, J.
    Huang, X-W.
    Ye, Q-H.
    Qiu, S-J.
    Zhou, J.
    Fan, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S824 - S824
  • [29] Camrelizumab combined with ablation and chemotherapy for pancreatic cancer with liver metastases: A single-arm, phase II, prospective clinical study.
    Li, Zhiwei
    Li, Qingwei
    Ma, Zhigang
    Ma, Yue
    Su, Dan
    Lou, Changjie
    Wang, Guangyu
    Liu, Chao
    Zhang, Yanqiao
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] Lenvatinib (LEN) combined with tislelizumab (TIS) plus transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II clinical trial
    Nong, Xiang
    Zhang, Yu-Mei
    Liang, Jing-Chang
    Xie, Jin-Long
    Zhang, Zhi-Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345